Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GeneDx Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GeneDx Holdings's regulatory disclosures and financial reporting.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.
On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.
A Form 144 notice shows a planned insider sale of 24,155 shares of Class A common stock, with an aggregate market value of $2,369,700. The shares are expected to be sold on or about 01/29/2026 on NASDAQ through Morgan Stanley Smith Barney.
The securities were acquired as compensation in the form of restricted stock units and performance-based restricted stock units on several dates between 2022 and 2025. The document also lists recent sales by Kevin Feeley over the past three months, including blocks such as 3,855 shares on 12/16/2025 for gross proceeds of $554,632.
WGS insider Katherine Stueland has filed a notice of proposed sale of 94,495 shares of Class A common stock through broker Morgan Stanley Smith Barney on NASDAQ. The filing lists an aggregate market value of 9268700 for these shares and shows 28,904,590 shares of this class outstanding.
The shares to be sold were acquired as equity compensation, including restricted stock units and performance-based restricted stock units granted between 2022 and 2025. The notice also reports prior sales over the last three months, including 2,158, 3,639, and 10,857 shares of Class A common stock, with stated gross proceeds for each transaction.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.
The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.
GeneDx Holdings Corp. (WGS) Form 4 shows Chief Financial Officer Kevin Feeley reported transactions on 09/16/2025 related to the vesting and settlement of restricted stock units (RSUs). 7,197 RSUs were treated as vested and settled for no cash consideration, and the Reporting Person triggered a sell-to-cover transaction that sold 3,728 shares at a weighted average price of $121.4727 to satisfy tax withholding. After these transactions, Mr. Feeley directly beneficially owned 8,755 shares of Class A common stock.
In addition to direct holdings, the filing discloses contingent rights to receive 124,633 RSU shares and options to purchase 27,152 shares, which vest over time per their terms. The sale is described as non-discretionary and solely to cover withholding obligations.
Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.
GeneDx Holdings Corp. reported that its Board of Directors appointed Thomas Fuchs, Dr.sc. as a Class I director, effective September 17, 2025. His term will run until the company’s 2028 Annual Meeting of Stockholders, and the Board size increased from seven to eight directors with this appointment.
Dr. Fuchs is the SVP and Chief AI Officer at Eli Lilly and Company, where he leads artificial intelligence initiatives across drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He has previously held senior academic and research roles in AI and computational pathology and founded several companies, including Paige AI.
Under GeneDx’s Non-Employee Director Compensation Policy, Dr. Fuchs will receive an initial restricted stock unit grant valued at $420,000, vesting over three years, subject to his continued service. The company also plans to enter into its standard form indemnity agreement with him, and there are no related-party transactions requiring disclosure in connection with his appointment.